

Alessandro Morabito

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3027257/publications.pdf>

Version: 2024-02-01

177
papers

8,371
citations

66336

42
h-index

53222

85
g-index

181
all docs

181
docs citations

181
times ranked

9853
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 924-937.	10.7	1,133
2	Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6865-6872.	1.6	452
3	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 897-907.	10.7	389
4	c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2702-2708.	1.6	380
5	Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 910-915.	1.6	361
6	Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. <i>Lancet Oncology</i> , The, 2003, 4, 605-615.	10.7	319
7	Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions. <i>Oncologist</i> , 2006, 11, 753-764.	3.7	245
8	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3002-3011.	1.6	229
9	Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3628-3635.	1.6	182
10	Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions. <i>Oncologist</i> , 2009, 14, 378-390.	3.7	176
11	Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1836-1843.	1.6	166
12	The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. <i>Cancer</i> , 1995, 76, 1772-1778.	4.1	162
13	Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 101, 355-365.	2.5	130
14	Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. <i>Cancer</i> , 1975, 35, 1108-1115.	4.1	119
15	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1379-1388.	10.7	119
16	Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. <i>Future Oncology</i> , 2018, 14, 2861-2874.	2.4	90
17	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. <i>Lancet Oncology</i> , The, 2007, 8, 500-512.	10.7	89
18	EGFR mutations in lung cancer: from tissue testing to liquid biopsy. <i>Future Oncology</i> , 2015, 11, 1611-1623.	2.4	82

#	ARTICLE	IF	CITATIONS
19	Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. <i>Oncotarget</i> , 2016, 7, 66595-66605.	1.8	78
20	Cisplatin Plus Gemcitabine or Vinorelbine for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The MILES-2P Studies. <i>Journal of Clinical Oncology</i> , 2007, 25, 4663-4669.	1.6	77
21	Angiogenesis Inhibitors in NSCLC. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2021.	4.1	73
22	Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBEO Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3192-3197.	1.6	71
23	Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. <i>European Journal of Cancer</i> , 2010, 46, 735-743.	2.8	71
24	Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. <i>Future Oncology</i> , 2019, 15, 2905-2914.	2.4	71
25	Treatment of pulmonary neuroendocrine tumours: State of the art and future developments. <i>Cancer Treatment Reviews</i> , 2013, 39, 466-472.	7.7	63
26	Target-based therapies in breast cancer: current status and future perspectives. <i>Endocrine-Related Cancer</i> , 2009, 16, 675-702.	3.1	62
27	Immunotherapy in Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 2522.	3.7	60
28	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	4.2	60
29	Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. <i>Cancer Journal From Scientific American</i> , 1999, 5, 101-11.	0.8	60
30	Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. <i>Lung Cancer</i> , 2004, 43, 83-91.	2.0	58
31	Treatment of small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 257-270.	4.4	57
32	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation. , 2020, 8, e001403.		57
33	Prognostic value of circulating tumor cells (CTCs) reduction in patients with extensive small-cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 314-319.	2.0	56
34	Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo) Tj ETQq0 0 0,rgBT /Overlock 10 Tf 262-273.	2.5	54
35	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1189.	7.1	53
36	The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Cancers</i> , 2019, 11, 341.	3.7	52

#	ARTICLE	IF	CITATIONS
37	Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study. <i>Lung Cancer</i> , 2013, 81, 77-83.	2.0	51
38	Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. <i>Future Oncology</i> , 2020, 16, 2799-2808.	2.4	50
39	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression \geq 50% and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	2.6	50
40	Is human hepatocellular carcinoma a hormone-responsive tumor?. <i>World Journal of Gastroenterology</i> , 2008, 14, 1682.	3.3	46
41	Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. <i>BMC Cancer</i> , 2008, 8, 252.	2.6	44
42	Metronomic administration of Zoledronic Acid and Taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial. <i>Cancer Biology and Therapy</i> , 2010, 10, 543-548.	3.4	44
43	A phase II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Annals of Oncology</i> , 1999, 10, 1377-1379.	1.2	43
44	Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2585-2592.	1.6	42
45	Therapy of breast cancer with molecular targeting agents. <i>Annals of Oncology</i> , 2005, 16, iv28-iv36.	1.2	41
46	Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , 2018, 19, 93-104.	2.6	41
47	Prognostic Significance of Necrosis, Elastosis, Fibrosis and Inflammatory Cell Reaction in Operable Breast Cancer. <i>Oncology</i> , 1995, 52, 272-277.	1.9	40
48	Angiogenesis Sustains Tumor Dormancy in Patients with Breast Cancer Treated with Adjuvant Chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2001, 65, 71-75.	2.5	39
49	Angiogenesis Inhibitors in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 655316.	2.8	38
50	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 461-465.	2.6	37
51	Antiangiogenic strategies, compounds, and early clinical results in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 49, 91-107.	4.4	36
52	Endocrine Effects of Adjuvant Letrozole + Triptorelin Compared With Tamoxifen + Triptorelin in Premenopausal Patients With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 264-270.	1.6	36
53	Thrombospondin-1 and -2 in Node-Negative Breast Cancer: Correlation with Angiogenic Factors, p53, Cathepsin D, Hormone Receptors and Prognosis. <i>Oncology</i> , 2001, 60, 72-80.	1.9	34
54	RET Inhibitors in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 4415.	3.7	34

#	ARTICLE	IF	CITATIONS
55	Vandetanib: An overview of its clinical development in NSCLC and other tumors. <i>Drugs of Today</i> , 2010, 46, 683.	1.1	34
56	Hormonal Treatment of Human Hepatocellular Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 252-261.	3.8	33
57	Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma. <i>PLoS ONE</i> , 2015, 10, e0139264.	2.5	33
58	Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 233-241.	4.4	32
59	Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. <i>Lung Cancer</i> , 2012, 76, 457-464.	2.0	32
60	Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology. <i>BioMed Research International</i> , 2013, 2013, 1-9.	1.9	32
61	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. <i>Journal of Translational Medicine</i> , 2014, 12, 291.	4.4	32
62	Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2009, 63, 251-258.	2.0	31
63	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 31-37.	2.0	31
64	Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. <i>American Journal of Kidney Diseases</i> , 1995, 26, 27-33.	1.9	30
65	Prognostic and Predictive Indicators in Operable Breast Cancer. <i>Clinical Breast Cancer</i> , 2003, 3, 381-390.	2.4	30
66	Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial. <i>Oncology</i> , 2009, 76, 49-54.	1.9	30
67	Methodological aspects of lung cancer clinical trials in the era of targeted agents. <i>Lung Cancer</i> , 2010, 67, 127-135.	2.0	30
68	CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). <i>British Journal of Cancer</i> , 1995, 71, 1283-1287.	6.4	28
69	Clinical Management of a Case of Recurrent Apocrine Gland Carcinoma of the Scalp: Efficacy of a Chemotherapy Schedule with Methotrexate and Bleomycin. <i>Tumori</i> , 2000, 86, 472-474.	1.1	28
70	Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF- β 1 and miRNA21 cooperation. <i>PLoS ONE</i> , 2019, 14, e0219597.	2.5	28
71	Safety and Activity of the Combination of Pegylated Liposomal Doxorubicin and Weekly Docetaxel in Advanced Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2004, 86, 249-258.	2.5	27
72	Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. <i>British Journal of Cancer</i> , 2006, 94, 1233-1236.	6.4	27

#	ARTICLE	IF	CITATIONS
73	Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 143-151.	4.4	27
74	Assessment of high-sensitive methods for the detection of <i>EGFR</i> mutations in circulating free tumor DNA from NSCLC patients. <i>Pharmacogenomics</i> , 2015, 16, 1135-1148.	1.3	26
75	Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls. <i>Cancers</i> , 2020, 12, 3804.	3.7	26
76	Methodology of clinical trials with new molecular-targeted agents: where do we stand?. <i>Annals of Oncology</i> , 2006, 17, vii128-vii131.	1.2	25
77	Systemic treatment of gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 216-234.	4.4	25
78	Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 166-170.	2.6	25
79	Evaluation of the VeriStrat [®] serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. <i>Lung Cancer</i> , 2017, 109, 101-108.	2.0	25
80	Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1086-1097.	1.1	25
81	Low-dose dopamine induces early recovery of recombinant interleukin-2-impaired renal function. <i>European Journal of Cancer</i> , 1993, 29, 1119-1122.	2.8	24
82	Combined Therapy with Weekly Irinotecan, Infusional 5-Fluorouracil and the Selective COX-2 Inhibitor Rofecoxib Is a Safe and Effective Second-Line Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2005, 10, 710-717.	3.7	24
83	Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. <i>BMC Cancer</i> , 2007, 7, 50.	2.6	23
84	Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 171-180.	4.4	23
85	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. <i>Lung Cancer</i> , 2010, 67, 86-92.	2.0	23
86	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1830-1844.	1.1	23
87	Risk Analysis in Healthcare Organizations: Methodological Framework and Critical Variables. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 2897-2911.	2.5	23
88	The Combination of Gemcitabine and Vinorelbine is an Active Regimen as Second-Line Therapy in Patients with Metastatic Breast Cancer Pretreated with Taxanes and/or Anthracyclines: a Phase II Study. <i>Breast Cancer Research and Treatment</i> , 2003, 78, 29-36.	2.5	22
89	Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. <i>Annals of Oncology</i> , 2012, 23, 2027-2033.	1.2	22
90	Cetuximab in non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 163-175.	2.4	22

#	ARTICLE	IF	CITATIONS
91	Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?. Expert Review of Anticancer Therapy, 2013, 13, 407-420.	2.4	22
92	A new look at the ALK gene in cancer: copy number gain and amplification. Expert Review of Anticancer Therapy, 2016, 16, 493-502.	2.4	22
93	The role of circulating free DNA in the management of NSCLC. Expert Review of Anticancer Therapy, 2019, 19, 19-28.	2.4	20
94	Gefitinib in Non Small Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-14.	3.0	19
95	Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues. Current Medicinal Chemistry, 2012, 19, 961-971.	2.4	19
96	Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization-based assay: Cytological smears versus cell blocks. Cancer Cytopathology, 2017, 125, 303-312.	2.4	19
97	Post-progression outcomes of NSCLC patients with PD-L1 expression \geq 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. European Journal of Cancer, 2021, 148, 24-35.	2.8	19
98	Surgery in Small-Cell Lung Cancer. Cancers, 2021, 13, 390.	3.7	17
99	A Delphi Consensus Approach for the Management of Chronic Pain during and after the COVID-19 Era. International Journal of Environmental Research and Public Health, 2021, 18, 13372.	2.6	17
100	Is tailored therapy feasible in oncology?. Critical Reviews in Oncology/Hematology, 2006, 57, 79-101.	4.4	16
101	Vinorelbine for non-small cell lung cancer. Expert Opinion on Drug Safety, 2010, 9, 493-510.	2.4	16
102	BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients. Lung Cancer, 2016, 95, 73-81.	2.0	16
103	New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group. Critical Reviews in Oncology/Hematology, 2017, 109, 35-41.	4.4	16
104	Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer, 2008, 60, 452-454.	2.0	15
105	Activity of Gefitinib in a Non-Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations. Journal of Thoracic Oncology, 2013, 8, e59-e60.	1.1	15
106	Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncology Reports, 2004, 11, 93-5.	2.6	15
107	Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. BMC Cancer, 2011, 11, 75.	2.6	13
108	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Review of Anticancer Therapy, 2013, 13, 1207-1218.	2.4	13

#	ARTICLE	IF	CITATIONS
109	CD90 Expression in Atypical Meningiomas and Meningioma Metastasis. <i>American Journal of Clinical Pathology</i> , 2014, 141, 841-849.	0.7	13
110	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. , 2020, 8, e001154.		13
111	The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients. <i>Lung Cancer</i> , 2008, 61, 67-72.	2.0	12
112	First-line systemic therapy for metastatic breast cancer and management of pleural effusion. <i>Annals of Oncology</i> , 1995, 6, 1033-1043.	1.2	11
113	First-Line Chemotherapy for HER-2â€“Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment. <i>Oncologist</i> , 2007, 12, 1288-1298.	3.7	11
114	Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the â€œpanaceaâ€™ for all patients?. <i>BMC Medicine</i> , 2018, 16, 24.	5.5	11
115	Novel Cytotoxic Chemotherapies in Small Cell Lung Carcinoma. <i>Cancers</i> , 2021, 13, 1152.	3.7	11
116	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. <i>EClinicalMedicine</i> , 2021, 37, 100940.	7.1	11
117	Cytosine arabinoside (Ara-C) plus alpha-interferon (α IFN) determine prolonged complete remissions in patients with aggressive non-Hodgkin's lymphoma partially responsive to first-line doxorubicin-containing regimens. <i>British Journal of Haematology</i> , 1994, 88, 421-423.	2.5	10
118	Selecting high-risk early breast cancer patients: What to add to the number of metastatic nodes?. <i>European Journal of Cancer</i> , 1996, 32, 41-46.	2.8	10
119	Doxorubicin-Docetaxel Sequential Schedule: Results of Front-Line Treatment in Advanced Breast Cancer. <i>Oncology</i> , 2002, 63, 205-212.	1.9	10
120	New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1503-1514.	4.1	10
121	Vandetanib as a potential treatment for breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1295-1303.	4.1	10
122	A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients. <i>Lung Cancer</i> , 2017, 108, 15-21.	2.0	10
123	Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications. <i>Translational Lung Cancer Research</i> , 2020, 9, 61-70.	2.8	10
124	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. <i>BMC Cancer</i> , 2021, 21, 549.	2.6	10
125	Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis. <i>International Journal of Oncology</i> , 1996, 8, 827-32.	3.3	9
126	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1021-1027.	2.3	8

#	ARTICLE	IF	CITATIONS
127	Positron Emission Tomography and Circulating Tumor Cells to Monitor a Dramatic Response to Gefitinib. <i>Journal of Thoracic Oncology</i> , 2012, 7, e27-e28.	1.1	8
128	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1653-1665.	2.8	8
129	Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 79-85.	2.2	7
130	Multiple effectiveness aspects of tapentadol for moderate–severe cancer-pain treatment: an observational prospective study. <i>Journal of Pain Research</i> , 2018, Volume 12, 117-125.	2.0	7
131	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. <i>Cancers</i> , 2019, 11, 1431.	3.7	7
132	Clinical trials and drug cost savings for Italian health service. <i>BMC Health Services Research</i> , 2020, 20, 1089.	2.2	7
133	Promising Role of Circulating Tumor Cells in the Management of SCLC. <i>Cancers</i> , 2021, 13, 2029.	3.7	7
134	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 57528-57536.	1.8	7
135	Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Betterâ€¦. <i>Current Pharmaceutical Design</i> , 2014, 20, 3901-3913.	1.9	7
136	Behaviour of metastasis in relation to vascular index in patients with node-positive breast cancer treated with adjuvant tamoxifen. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 15-20.	3.3	6
137	Thalidomide Is Inactive in Heavily Pretreated Patients with Metastatic Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2005, 11, 248-251.	2.0	6
138	Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology. <i>PLoS ONE</i> , 2019, 14, e0210330.	2.5	6
139	Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. <i>Oncology Reports</i> , 0, , .	2.6	6
140	Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial. <i>Journal of Thoracic Oncology</i> , 2012, 7, 233-242.	1.1	5
141	Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, e86-e88.	1.2	5
142	Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is â€œpromotedâ€™!. <i>Annals of Oncology</i> , 2019, 30, 165-167.	1.2	5
143	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. <i>Lung Cancer</i> , 2019, 133, 62-68.	2.0	5
144	Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4927.	4.1	5

#	ARTICLE	IF	CITATIONS
145	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	17.0	5
146	High-dose recombinant interleukin-2/verapamil combination in advanced cancer. <i>European Journal of Cancer</i> , 1996, 32, 1436-1437.	2.8	4
147	A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer. <i>Oncology</i> , 1999, 56, 267-273.	1.9	4
148	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2011, Volume 4, 1-9.	0.7	4
149	Pembrolizumab in lung cancer: current evidence and future perspectives. <i>Future Oncology</i> , 2019, 15, 3327-3336.	2.4	4
150	Small Cell Lung Cancer: A New Era Is Beginning?. <i>Cancers</i> , 2021, 13, 2646.	3.7	4
151	Single agent vs combination chemotherapy (CT) as second-line treatment of advanced non-small-cell lung cancer (NSCLC): A meta-analysis of individual data of five randomized trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 8052-8052.	1.6	4
152	Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern Italy. <i>Anticancer Research</i> , 2016, 36, 2119-24.	1.1	4
153	Multiorganic Dissemination of a Colorectal Signet Ring Cell Carcinoma with Fulminant Clinical Course. <i>International Journal of Gastrointestinal Cancer</i> , 2006, 37, 49-54.	0.4	3
154	Methodological Issues of Clinical Research with EGFR Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 292-302.	0.3	3
155	Trastuzumab Beyond Progression: Is the Risk of Cardiac Toxicity Really Not Increased?. <i>Journal of Clinical Oncology</i> , 2009, 27, e123-e123.	1.6	3
156	Time Spent for Activation of Non-Profit Studies in Oncology in Italy. <i>PLoS ONE</i> , 2010, 5, e11864.	2.5	3
157	Induction Therapy for Lung Cancer: Sailing Across the Pillars of Hercules. <i>Thoracic Surgery Clinics</i> , 2012, 22, 67-75.	1.0	3
158	P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2217-S2218.	1.1	3
159	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th), Tj ETQq1 1 0,784314	4.4	3
160	Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 844-851.	1.7	3
161	Validation of the new IASLC/ATS/ERS lung adenocarcinoma classification: a surgeon's perspective. <i>Journal of Thoracic Disease</i> , 2014, 6, S547-51.	1.4	3
162	High dose chemotherapy with epirubicin (E) and cyclophosphamide (C) plus hemopoietic colony stimulating factors in locally advanced (LABC) or metastatic (MBC) breast cancer. A phase II trial. <i>European Journal of Cancer</i> , 1993, 29, S57.	2.8	2

#	ARTICLE	IF	CITATIONS
163	Phase I study of carboplatin, cisplatin, and cyclophosphamide without and with lenograstim for the treatment of ovarian cancer. <i>International Journal of Oncology</i> , 1997, 11, 175.	3.3	2
164	EGFR Mutations. , 2019, , 477-486.		2
165	The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 775-783.	2.4	2
166	Phase II study of celecoxib and weekly paclitaxel in the treatment of pretreated advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2004, 22, 7337-7337.	1.6	2
167	Tailored therapy for aggressive non-Hodgkin's lymphoma: results of a phase II study with a long-term follow-up.. <i>International Journal of Oncology</i> , 1998, 13, 121-7.	3.3	1
168	Clinical benefit of intermittent administration of imatinib in a patient with metastatic gastrointestinal stromal tumour. <i>Clinical Oncology</i> , 2005, 17, 96-97.	1.4	1
169	Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. <i>Oncology Reports</i> , 2006, 16, 393.	2.6	1
170	Prognostic evaluation and choice of second-line treatment for patients with advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 55-62.	1.5	1
171	Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer. , 2020, 1, 117-130.		1
172	Failure of a Cetuximab/Bevacizumab Schedule in a Patient with Metastatic Desmoplastic Small Round-cell Tumour Refractory to Chemotherapy. <i>Clinical Oncology</i> , 2005, 17, 393-394.	1.4	0
173	Lungs on Fire. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1376.	1.1	0
174	Chemotherapy for Metastatic Breast Cancer Patients Who Received Adjuvant Anthracyclines (An) Tj ETQqO O O rgBT /Overlock 10 Tf 50		0
175	Integration of Target-Based Agents in Current Protocols of Breast Cancer Therapy. , 2009, , 203-224.		0
176	ZEPHYR: failure of a "spring wind" in lung cancer. <i>Translational Lung Cancer Research</i> , 2013, 2, E4-6.	2.8	0
177	Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations. <i>Global & Regional Health Technology Assessment</i> , 0, 9, 22-29.	0.1	0